- Home
- CNXN vs IMNM Comparison
CNXN vs IMNM Comparison
Compare CNXN & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNXN
- IMNM
- Stock Information
- Founded
- CNXN 1982
- IMNM 2006
- Country
- CNXN United States
- IMNM United States
- Employees
- CNXN N/A
- IMNM N/A
- Industry
- CNXN Catalog/Specialty Distribution
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- CNXN Consumer Discretionary
- IMNM Health Care
- Exchange
- CNXN Nasdaq
- IMNM Nasdaq
- Market Cap
- CNXN N/A
- IMNM 747.7M
- IPO Year
- CNXN 1998
- IMNM 2020
- Fundamental
- Price
- CNXN $73.69
- IMNM $12.23
- Analyst Decision
- CNXN
- IMNM Strong Buy
- Analyst Count
- CNXN 0
- IMNM 4
- Target Price
- CNXN N/A
- IMNM $28.75
- AVG Volume (30 Days)
- CNXN 115.2K
- IMNM 883.2K
- Earning Date
- CNXN 10-30-2024
- IMNM 11-07-2024
- Dividend Yield
- CNXN 0.54%
- IMNM N/A
- EPS Growth
- CNXN 17.07
- IMNM N/A
- EPS
- CNXN 3.35
- IMNM N/A
- Revenue
- CNXN $2,758,056,000.00
- IMNM $10,784,000.00
- Revenue This Year
- CNXN $2.01
- IMNM N/A
- Revenue Next Year
- CNXN $7.29
- IMNM N/A
- P/E Ratio
- CNXN $22.00
- IMNM N/A
- Revenue Growth
- CNXN N/A
- IMNM 62.73
- 52 Week Low
- CNXN $51.64
- IMNM $6.93
- 52 Week High
- CNXN $77.19
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- CNXN 52.69
- IMNM 36.79
- Support Level
- CNXN $72.40
- IMNM $12.24
- Resistance Level
- CNXN $74.83
- IMNM $13.40
- Average True Range (ATR)
- CNXN 1.40
- IMNM 0.77
- MACD
- CNXN -0.27
- IMNM -0.24
- Stochastic Oscillator
- CNXN 27.69
- IMNM 14.41
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.